Spencer C A, Platler B W, Guttler R B, Nicoloff J T
Clin Chim Acta. 1985 Sep 30;151(2):121-32. doi: 10.1016/0009-8981(85)90315-8.
This study was undertaken to evaluate the heterogeneity and stability of 125I-labeled human thyroglobulin (Tg) tracers. Tg, labeled with 125I by either a Chloramine T (CT) or a Glucose Oxidase/Lactoperoxidase (GO) method, showed considerable heterogeneity of labeled components, the relative proportions of which were a function of the Tg preparation and the iodination method used. The four largest components had apparent molecular weights as follows: A = 1 200 000 Da; B = 670 000 Da; C = 530 000 Da and D = 290 000 Da. Both B and C were immunoactive. B was considered to be 19S Tg. A non-specific binding difference, (NSB delta) between nonhuman matrices used for diluting standards and human sera was found for the partly immunoactive aggregate component A, (5-20%) and the nonimmunoactive component D, (20-50%), but was minimally present for components B and C (less than 5%). The [125I]19S Tg(B), stored at -70 degrees C, showed rapid spontaneous decomposition with time (50% lost by 8 days), with generation of C, D and iodide. The loss of B was related to specific activity and was least in GO labels. 125I labeling of Tg by GO produced tracers with better immunoactivity, stability and lower NSB delta than comparative CT tracers. Definitive purification and repurification of [125I]Tg tracers before use is necessary in order to remove degradation products with the potential to compromise the accuracy and specificity of serum Tg radioimmunoassay (RIA) measurement.
本研究旨在评估125I标记的人甲状腺球蛋白(Tg)示踪剂的异质性和稳定性。通过氯胺T(CT)法或葡萄糖氧化酶/乳过氧化物酶(GO)法用125I标记的Tg显示出标记成分的显著异质性,其相对比例是Tg制剂和所用碘化方法的函数。四个最大的成分的表观分子量如下:A = 1200000 Da;B = 670000 Da;C = 530000 Da和D = 290000 Da。B和C都具有免疫活性。B被认为是19S Tg。对于用于稀释标准品的非人基质和人血清,发现部分具有免疫活性的聚集成分A(5 - 20%)和非免疫活性成分D(20 - 50%)存在非特异性结合差异(NSBδ),但成分B和C的差异最小(小于5%)。[125I]19S Tg(B)在-70℃储存时,随时间显示出快速的自发分解(8天内损失50%),生成C、D和碘化物。B的损失与比活性有关,在GO标记中损失最少。与对照CT示踪剂相比,通过GO法对Tg进行125I标记产生的示踪剂具有更好的免疫活性、稳定性和更低的NSBδ。为了去除可能会影响血清Tg放射免疫分析(RIA)测量准确性和特异性的降解产物,在使用前对[125I]Tg示踪剂进行最终纯化和再纯化是必要的。